Press Releases

Press Releases

INDI® APPOINTS STEVEN SPRINGMEYER CMO

SEATTLE, June 16, 2015 – Indi (Integrated Diagnostics®), a molecular diagnostics company pioneering the use of blood-based proteomic tests, today announced that it has appointed Steven Springmeyer, M.D., as chief medical officer. Indi is the creator of Xpresys® Lung, the first non-invasive molecular blood test for the assessment of pulmonary nodules. Springmeyer is a distinguished pulmonary and critical care specialist who most recently served as medical director and vice president of Spiration.

"As Indi continues to expand the market for Xpresys Lung and to explore new applications for our proteomics platform, Steve’s demonstrated leadership in pulmonary medicine will prove invaluable,” said Albert A. Luderer, Ph.D., chief executive officer, Indi. “Steve’s successful track record as a leader at a successfully acquired medical device startup makes him the perfect fit.”

Prior to his leadership role at Spiration, a company that specializes in minimally invasive devices for lung conditions and that was acquired by Olympus Corporation in 2010, Springmeyer spent 17 years at Virginia Mason Medical Center in Seattle, most recently as director of bronchoscopy and interventional pulmonology and co-director of thoracic oncology. Prior to that, Springmeyer spent a decade at the University of Washington, rising to become chief of respiratory disease at the Fred Hutchinson Cancer Research Center.

"Indi’s technology and vision for noninvasive blood tests has the potential to change the practice of diagnostic medicine,” said Springmeyer. “The company’s success at garnering insurance coverage for Xpresys Lung shows its strong potential for reducing unnecessary invasive procedures and lowering costs. I’m thrilled to be working alongside Al and the entire team to fulfill the promise of Xpresys Lung and Indi’s proteomics platform."

Springmeyer holds a B.S. in biology and an M.D. from the University of Utah in Salt Lake City.

About Xpresys Lung

Xpresys Lung is a breakthrough protein expression blood test developed to provide physicians with a solution to a major medical dilemma in the United States—the overtreatment of benign lung nodules. Today, it is estimated millions of pulmonary nodules are discovered each year; after traditional assessment protocols, which include biopsies and surgeries, most of these nodules are classified as benign. Xpresys Lung allows for the non-invasive assessment of pulmonary nodules in the 8-30 mm size range; traditionally, nodules of this size are associated with significant diagnostic uncertainty.

Xpresys Lung provides physicians with objective information to help them identify nodules with a high probability of being benign, potentially reducing unnecessary invasive procedures which may be risky for the patient and costly to the healthcare system.

The blood test measures the relative abundance of proteins from multiple pathways associated with lung cancer, using a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec).

Xpresys Lung is supported by a landmark clinical validation study published in The Journal of Thoracic Oncology in January 2015 and two studies published in Science Translational Medicine in October 2013. Click here to access the STM study.

About Indi

Indi (Integrated Diagnostics) is redefining molecular diagnostics and creating powerful new tools for physicians to non-invasively assess and more effectively manage complex diseases to improve patient outcomes, reduce complications, and lessen costs to the healthcare system. With the company’s first breakthrough test, Xpresys Lung, which measures multiple blood proteins and identifies lung nodules with a high probability of being benign, physicians have the potential to reduce risks and the need for unnecessary invasive procedures.

The company was co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, who recently received the National Medal of Science from the U.S. government. His groundbreaking research is based on a systems biology approach, which measures hundreds of protein biomarkers found in blood to report on the physiological state of the body’s 50 major organs, such as the lungs.

Backers include Baird Capital, InterWest Partners, Life Sciences Alternative Financing and the Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com

 
 
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue